Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Common Equity: 2012-2025

Historic Common Equity for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $1.3 billion.

  • Agios Pharmaceuticals' Common Equity fell 21.05% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 21.05%. This contributed to the annual value of $1.5 billion for FY2024, which is 90.00% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Common Equity stood at $1.3 billion, which was down 6.22% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Common Equity ranged from a high of $2.3 billion in Q1 2021 and a low of $660.5 million during Q2 2024.
  • In the last 3 years, Agios Pharmaceuticals' Common Equity had a median value of $1.0 billion in 2023 and averaged $1.1 billion.
  • Per our database at Business Quant, Agios Pharmaceuticals' Common Equity surged by 267.29% in 2021 and then slumped by 47.43% in 2022.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Common Equity stood at $1.3 billion in 2021, then declined by 14.80% to $1.1 billion in 2022, then decreased by 26.33% to $811.0 million in 2023, then soared by 90.00% to $1.5 billion in 2024, then fell by 21.05% to $1.3 billion in 2025.
  • Its Common Equity stands at $1.3 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.5 billion for Q1 2025.